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Prevention is always better than cure, and this also goes for
anaemia in preterm neonates. Prevention of neonatal anae-
mia can partly be achieved by strategies including delayed
cord clamping and reduction of blood loss by limiting labo-
ratory investigations and using micro-blood testing. Despite
the implementation of these measures in the past decades,
neonatologists can still not do without the use of red blood
cell (RBC) transfusions. Nearly all extremely preterm neo-
nates (i.e. born before 28 weeks of gestation) receive at least
one RBC transfusion in the first weeks of life due to severe
anaemia.1,2 On average they require three to four transfu-
sions until discharge, but it is not unusual for a neonate
born at 23–24 weeks of gestation to receive up to 10 transfu-
sions. These patterns of use of RBC transfusions are seen
despite general recommendations for restrictive transfusion
policies.2
Although RBC transfusions are generally considered to be
safe, complications might be under-recognised in the preterm
neonatal population due to concomitant severe morbidity.
Recent studies in preterm neonates suggested an association
between RBC transfusions and various complications includ-
ing transfusion-associated necrotising enterocolitis, bron-
chopulmonary dysplasia, retinopathy of prematurity (ROP)
and also increased mortality.2 Whether the association
between the RBC transfusions and these complications also
reflects causality is to date unclear.3
Indeed, the underlying pathophysiological link between
RBC transfusions and these severe complications is not
known. Some authors have postulated that this could be due
to the characteristics and type of the blood component, in
addition to the uncertain implications of transfusing a pro-
duct collected from adult donors.4 A standard RBC product
contains predominantly adult haemoglobin (HbA), whereas
(preterm) neonates have a predominance of fetal Hb (HbF)
at birth. After birth, HbF gradually declines and finally disap-
pears by 1–2 years of age. Importantly, HbA (a2b2) and
HbF (a2c2) have very distinct characteristics, as HbF has a
greater affinity for oxygen compared to HbA, a crucial and
beneficial characteristic in the fetal period. Thanks to the
greater oxygen affinity, the oxygen-haemoglobin dissociation
curve is shifted to the left, enabling fetuses to subtract oxy-
gen from the maternal circulation into the placental (and
fetal) circulation. The greater oxygen affinity of HbF is partly
related to lower levels of 2,3 diphosphoglycerate, a glycolysis
product that enhances the ability of RBCs to release oxygen
near tissues that need it most. Predominance of HbF in pre-
term neonates therefore complicates the unloading of oxygen
to the tissues. In turn, increase of HbA in preterm neonates
with blood transfusions will automatically increase the oxy-
gen availability to these tissues and end-organs. In the case
of the retina, this sudden increase in HbA and higher oxygen
delivery could contribute to the development of ROP and
blindness.5
A physiological (and most logical) alternative to avoid this
transfusion-induced unphysiological increase of HbA in pre-
term neonates would be to use placental blood (which con-
tains predominantly HbF) as a source of RBCs. The use of
placental blood, also termed as umbilical cord blood (UCB)
as it is harvested by drawing blood from the cord after birth,
was first described almost a century ago.6 Unfortunately, it
never got enough attention, until a few decades ago when
renewed interest in use of placental blood was described. Sev-
eral studies evaluated the possibility of using autologous
blood transfusion for extremely preterm neonates by harvest-
ing UCB at birth from their own placenta and processing
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this to an autologous RBC product for own use.4,7 However,
as shown by researchers at our centre, harvesting and pro-
cessing UCB from preterm placentas is technically very chal-
lenging with as a principal limitation the low volume of
blood collected from the small preterm placentas.4,7 A pla-
centa from a preterm neonate with a birth weight of 1 kg
often yielded <15 ml of blood, whereas extremely preterm
neonates need up to 45–60 ml (three to four transfusions at
15 ml/kg) of RBC transfusions until discharge. Therefore,
only up to one-third of the needed blood could be derived
from autologous UCB.8
In this present issue, Bianchi et al.8 discuss the effects and
advantages of the logical alternative: namely allogeneic UCB,
drawn from placentas from term neonates to transfuse pre-
term neonates. Term placentas allow the collection of a
much larger volume of blood around, on average 80–100 ml,
which could (in theory) fulfil the transfusion needs of an
extremely preterm neonate. This Italian research group has
extensive experience with allogeneic UCB transfusion, and
were the first to suggest its use in 2015.9 In the present
study, the authors evaluated the use of UCB in very preterm
neonates (<30 weeks of gestation) as an alternative to the
traditional blood component processed from adult donors.
The choice of the product in this non-randomised study was
based on availability of ABO- and Rh-matched cord blood
units: if available, preterm neonates received UCB instead of
adult blood. The authors measured the HbF percentage until
36 weeks post-menstrual age and, unsurprisingly, found that
neonates transfused with UCB maintained high HbF percent-
ages as compared to those transfused with adult blood expe-
riencing a significant drop in HbF. Because the study was
not designed to assess clinical effects, the authors could not
reliably assess if higher HbF percentages also reduced the
occurrence and severity of diseases such as ROP.
A number of important issues follow-on from the
reported elegant and promising strategy to use allogeneic
UCB for preterm neonates. There were challenges in provid-
ing sufficient UCB. Despite their experience with this strat-
egy, only a minority (two of nine) of the transfused neonates
in this study received ‘UCB-blood-only’ due to lack of avail-
ability of matched UCB. As rightly commented by the
authors, an extensive collaboration between cord blood banks
is required in order to implement an optimal and efficient
allogeneic UCB strategy that does not interfere with the other
use of UCB, namely as haematopoietic stem cell source.
Other issues that need further work, relate to allogeneic
blood appropriate typing, and serological/polymerase chain
reaction testing but because of the semi-aseptic acquisition
method of UCB probably also additional negativity of micro-
bial cultures. Finally, the influence of storage conditions
should be validated.
All the latter issues need to be tackled before safe and
robust use of allogeneic UCB becomes possible and with it
randomised controlled trials (RCTs) that will provide the
true ‘proof of the pudding’. Evidently, such RCTs should
show that allogeneic UCBs as compared to ‘standard of care’
blood components from adult donors indeed reduce transfu-
sion-associated morbidity and mortality. In this respect, this
study shows that allogeneic UCB transfusions in extremely
preterm neonates is a feasible and promising proof of con-
cept that deserves further pursuit.
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